Elizabeth Selvin1, Andreea M Rawlings2, Pamela L Lutsey2, Nisa Maruthur2, James S Pankow2, Michael Steffes2, Josef Coresh2. 1. From Department of Epidemiology and the Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., A.M.R., J.C.); Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD (E.S., N.M., J.C.); Division of Epidemiology & Community Health (P.L.L., J.S.P.) and Department of Laboratory Medicine and Pathology (M.S.), University of Minnesota, Minneapolis. eselvin@jhu.edu. 2. From Department of Epidemiology and the Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S., A.M.R., J.C.); Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD (E.S., N.M., J.C.); Division of Epidemiology & Community Health (P.L.L., J.S.P.) and Department of Laboratory Medicine and Pathology (M.S.), University of Minnesota, Minneapolis.
Abstract
BACKGROUND: Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. METHODS AND RESULTS: We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and-as has been previously observed for HbA1c-the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. CONCLUSIONS: The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.
BACKGROUND: Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. METHODS AND RESULTS: We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and-as has been previously observed for HbA1c-the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker. CONCLUSIONS: The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.
Authors: David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan Journal: Clin Chem Date: 2011-05-26 Impact factor: 8.327
Authors: Audrey Yondjeu Nouya; Jobert Richie N Nansseu; Vicky Joceline Ama Moor; Constant Anatole Pieme; Jean Jacques N Noubiap; Corinne M Tchoula; Bruno M Mokette; Ruth Danielle M Takam; Francine Tankeu; Jeanne Yonkeu Ngogang; Andre Pascal Kengne Journal: Diabetes Res Clin Pract Date: 2014-10-24 Impact factor: 5.602
Authors: Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: Elizabeth Selvin; Lesley M A Francis; Christie M Ballantyne; Ron C Hoogeveen; Josef Coresh; Frederick L Brancati; Michael W Steffes Journal: Diabetes Care Date: 2011-02-18 Impact factor: 19.112
Authors: Emanuele Di Angelantonio; Pei Gao; Hassan Khan; Adam S Butterworth; David Wormser; Stephen Kaptoge; Sreenivasa Rao Kondapally Seshasai; Alex Thompson; Nadeem Sarwar; Peter Willeit; Paul M Ridker; Elizabeth L M Barr; Kay-Tee Khaw; Bruce M Psaty; Hermann Brenner; Beverley Balkau; Jacqueline M Dekker; Debbie A Lawlor; Makoto Daimon; Johann Willeit; Inger Njølstad; Aulikki Nissinen; Eric J Brunner; Lewis H Kuller; Jackie F Price; Johan Sundström; Matthew W Knuiman; Edith J M Feskens; W M M Verschuren; Nicholas Wald; Stephan J L Bakker; Peter H Whincup; Ian Ford; Uri Goldbourt; Agustín Gómez-de-la-Cámara; John Gallacher; Leon A Simons; Annika Rosengren; Susan E Sutherland; Cecilia Björkelund; Dan G Blazer; Sylvia Wassertheil-Smoller; Altan Onat; Alejandro Marín Ibañez; Edoardo Casiglia; J Wouter Jukema; Lara M Simpson; Simona Giampaoli; Børge G Nordestgaard; Randi Selmer; Patrik Wennberg; Jussi Kauhanen; Jukka T Salonen; Rachel Dankner; Elizabeth Barrett-Connor; Maryam Kavousi; Vilmundur Gudnason; Denis Evans; Robert B Wallace; Mary Cushman; Ralph B D'Agostino; Jason G Umans; Yutaka Kiyohara; Hidaeki Nakagawa; Shinichi Sato; Richard F Gillum; Aaron R Folsom; Yvonne T van der Schouw; Karel G Moons; Simon J Griffin; Naveed Sattar; Nicholas J Wareham; Elizabeth Selvin; Simon G Thompson; John Danesh Journal: JAMA Date: 2014-03-26 Impact factor: 56.272
Authors: Christina M Parrinello; A Richey Sharrett; Nisa M Maruthur; Richard M Bergenstal; Morgan E Grams; Josef Coresh; Elizabeth Selvin Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Christina W Chen; Christiane Drechsler; Pirianthini Suntharalingam; S Ananth Karumanchi; Christoph Wanner; Anders H Berg Journal: Clin Chem Date: 2016-10-13 Impact factor: 8.327
Authors: Christine L Chan; Laura Pyle; Megan M Kelsey; Lindsey Newnes; Amy Baumgartner; Philip S Zeitler; Kristen J Nadeau Journal: Pediatr Diabetes Date: 2016-11-22 Impact factor: 4.866
Authors: Ning Ding; Lucia Kwak; Shoshana H Ballew; Bernard Jaar; Ron C Hoogeveen; Christie M Ballantyne; A Richey Sharrett; Aaron R Folsom; Gerardo Heiss; Maya Salameh; Josef Coresh; Alan T Hirsch; Elizabeth Selvin; Kunihiro Matsushita Journal: Atherosclerosis Date: 2018-04-30 Impact factor: 5.162
Authors: Sidar Copur; Dimitrie Siriopol; Baris Afsar; Melis C Comert; Gizem Uzunkopru; Alan A Sag; Alberto Ortiz; Adrian Covic; Daniel H van Raalte; David Z Cherney; Peter Rossing; Mehmet Kanbay Journal: Acta Diabetol Date: 2020-08-30 Impact factor: 4.280
Authors: Leila R Zelnick; Zona O Batacchi; Iram Ahmad; Ashveena Dighe; Randie R Little; Dace L Trence; Irl B Hirsch; Ian H de Boer Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112